Show simple item record

dc.contributor.authorMallat, Ziad
dc.contributor.authorSteg, Phillippe Gabriel
dc.contributor.authorBenessiano, Joelle
dc.contributor.authorTanguy, Marie-Laure
dc.contributor.authorFox, Keith A. A.
dc.contributor.authorCollet, Jean-Philippe
dc.contributor.authorDabbous, Omar H.
dc.contributor.authorHenry, Patrick
dc.contributor.authorCarruthers, Kathryn F.
dc.contributor.authorDauphin, Anne
dc.contributor.authorArguelles, Carla Sibella
dc.contributor.authorMasliah, Joelle
dc.contributor.authorHugel, Benedicte
dc.contributor.authorMontalescot, Gilles
dc.contributor.authorFreyssinet, Jean-Marie
dc.contributor.authorAsselain, Bernard
dc.contributor.authorTedgui, Alain
dc.date2022-08-11T08:08:09.000
dc.date.accessioned2022-08-23T15:44:09Z
dc.date.available2022-08-23T15:44:09Z
dc.date.issued2005-10-04
dc.date.submitted2011-09-23
dc.identifier.citationJ Am Coll Cardiol. 2005 Oct 4;46(7):1249-57. <a href="http://dx.doi.org/10.1016/j.jacc.2005.06.056">Link to article on publisher's site</a>
dc.identifier.issn0735-1097 (Linking)
dc.identifier.doi10.1016/j.jacc.2005.06.056
dc.identifier.pmid16198839
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27252
dc.description.abstractOBJECTIVES: The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS). BACKGROUND: The plasma level of type IIA sPLA2 is a risk factor for coronary artery disease (CAD) and is associated with adverse outcomes in patients with stable CAD. The prognostic impact of sPLA2 in patients with ACS is unknown. METHODS: Secretory phospholipase A2 antigen levels and activity were measured in plasma samples of 446 patients with ACS, obtained at the time of enrollment. RESULTS: Baseline sPLA2 activity was associated with the risk of death and myocardial infarction (MI). The unadjusted rate of death and MI increased in a stepwise fashion with increasing tertiles of sPLA2 activity (p < 0.0001). The association remained significant in the subgroup of patients who had MI with ST-segment elevation (p = 0.014) and the subgroup of patients who had unstable angina or non-ST-segment elevation MI (p < 0.002). After adjustment for clinical and biological variables, the hazard ratios for the combined end point of death or MI in the third tertile of sPLA2 compared with the first and second tertiles was 3.08 (95% confidence interval, 1.37 to 6.91, p = 0.006). CONCLUSIONS: A single measurement of plasma sPLA2 activity at the time of enrollment provides strong independent information to predict recurrent events in patients with ACS.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=16198839&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.jacc.2005.06.056
dc.subjectAcute Disease
dc.subjectAngina, Unstable
dc.subjectC-Reactive Protein
dc.subjectFemale
dc.subjectHumans
dc.subjectInterleukin-18
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocardial Infarction
dc.subjectPhospholipases A
dc.subjectPhospholipases A2
dc.subjectPrognosis
dc.subjectRecurrence
dc.subjectSeverity of Illness Index
dc.subjectHealth Services Research
dc.titleCirculating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
dc.typeJournal Article
dc.source.journaltitleJournal of the American College of Cardiology
dc.source.volume46
dc.source.issue7
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cor_grace/70
dc.identifier.contextkey2254991
html.description.abstract<p>OBJECTIVES: The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS).</p> <p>BACKGROUND: The plasma level of type IIA sPLA2 is a risk factor for coronary artery disease (CAD) and is associated with adverse outcomes in patients with stable CAD. The prognostic impact of sPLA2 in patients with ACS is unknown.</p> <p>METHODS: Secretory phospholipase A2 antigen levels and activity were measured in plasma samples of 446 patients with ACS, obtained at the time of enrollment.</p> <p>RESULTS: Baseline sPLA2 activity was associated with the risk of death and myocardial infarction (MI). The unadjusted rate of death and MI increased in a stepwise fashion with increasing tertiles of sPLA2 activity (p < 0.0001). The association remained significant in the subgroup of patients who had MI with ST-segment elevation (p = 0.014) and the subgroup of patients who had unstable angina or non-ST-segment elevation MI (p < 0.002). After adjustment for clinical and biological variables, the hazard ratios for the combined end point of death or MI in the third tertile of sPLA2 compared with the first and second tertiles was 3.08 (95% confidence interval, 1.37 to 6.91, p = 0.006).</p> <p>CONCLUSIONS: A single measurement of plasma sPLA2 activity at the time of enrollment provides strong independent information to predict recurrent events in patients with ACS.</p>
dc.identifier.submissionpathcor_grace/70
dc.contributor.departmentCenter for Outcomes Research
dc.source.pages1249-57


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record